PA5-14973

antibody from Invitrogen Antibodies

Targeting: MUC20 FLJ14408, KIAA1359

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-14973

Provider

Invitrogen Antibodies

Product name

MUC20 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

400 µL

Concentration

2 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.

Wang X, Shirazi F, Yan W, Liu X, Wang H, Orlowski RZ, Wang H
Journal of cellular and molecular medicine 2021 Nov;25(21):10164-10174

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of WiDr cells using a MUC20 polyclonal antibody (Product # PA5-14973) at a dilution of 1:10-50, followed by a fluor-conjugated goat anti-rabbit secondary antibody (green). Actin filaments were stained with dye-conjugated phalloidin (red). Nuclei were stained with DAPI (blue).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of WiDr cells using a MUC20 polyclonal antibody (Product # PA5-14973) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 3 MUC20 expression correlates with proteasome inhibitor sensitivity. (A) Mantle cell lymphoma (MCL) cells were infected with cDNA, which led to MUC20 overexpression (MUC20-OE). Real-time polymerase chain reaction (PCR) detection of MUC20 mRNA and (B) Western blotting analysis of MUC20 protein levels to identify the infection effect. (C) Viability of CR cells compared with CR/MUC20-overexpressing (MUC20-OE) MCL cells in carfilzomib for 48 h. (D) Immunodeficient mice were randomly divided into four groups. Two groups were subcutaneously implanted with Granta-519/CR cells and two were implanted with Granta-519/CR/MUC20-OE cells. One Granta-519/CR group and one Granta-519/CR/MUC20-OE group were treated with 5 mg/kg CFZ by intraperitoneal injection twice a week. The other groups were treated with normal saline (NS) as a control. The expressions of MUC20, p-c-Met and p-ERK1/2 in mice are shown. (E) Tumours in mice are shown. (F) The weight of tumours. (G) Tumour growth according to calliper measurement, which was calculated as the tumour volume using the equation (0.4 x L x W2). * p < 0.05

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIGURE 2 MUC20 expression decreased in mantle cell lymphoma (MCL) cells treated with proteasome inhibitors (PIs). (A) Real-time polymerase chain reaction (RT-PCR) analysis of MUC20 mRNA content in carfilzomib-resistant (CR) cells compared with their wild-type (WT) counterparts. (B) Western blotting analysis of MUC20 protein levels in the WT and CR cell lines. (C) Flow cytometry analysis of membrane MUC20 expression in the WT and CR cell lines. (D, E) Flow cytometry analysis of MUC20 expression on CD20 + populations from the bone marrow (BM) of nine MCL patients (newly diagnosed and exposed to bortezomib). * p < 0.05. RR, relapse and resistance to bortezomib; ND, newly diagnosed